Myriad Genetics, Inc. (NASDAQ:MYGN) was up 6.5% during mid-day trading on Tuesday following a better than expected earnings announcement. The company traded as high as $30.47 and last traded at $30.30. Approximately 1,901,180 shares were traded during trading, an increase of 98% from the average daily volume of 961,910 shares. The stock had previously closed at $28.45.

The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The firm had revenue of $190.20 million for the quarter, compared to the consensus estimate of $183.52 million. During the same quarter in the prior year, the business earned $0.23 earnings per share. The company’s revenue was up 7.2% compared to the same quarter last year.

A number of analysts have recently commented on MYGN shares. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Monday, July 17th. Morgan Stanley reaffirmed an “underweight” rating and issued a $24.00 price target (up previously from $17.00) on shares of Myriad Genetics in a report on Friday, October 6th. BidaskClub cut Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Cowen and Company reaffirmed a “hold” rating and issued a $25.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $31.00 price target on shares of Myriad Genetics in a report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $26.40.

In related news, Director John T. Henderson sold 30,000 shares of the company’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $30.30, for a total value of $909,000.00. Following the completion of the transaction, the director now owns 52,524 shares of the company’s stock, valued at approximately $1,591,477.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.70% of the company’s stock.

Several institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services Inc acquired a new position in shares of Myriad Genetics during the third quarter valued at approximately $202,000. Russell Investments Group Ltd. raised its holdings in shares of Myriad Genetics by 7.3% during the third quarter. Russell Investments Group Ltd. now owns 1,151,915 shares of the company’s stock valued at $41,676,000 after acquiring an additional 78,798 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Myriad Genetics during the third quarter valued at approximately $204,000. Rhumbline Advisers raised its holdings in shares of Myriad Genetics by 2.7% during the third quarter. Rhumbline Advisers now owns 137,380 shares of the company’s stock valued at $4,970,000 after acquiring an additional 3,575 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its holdings in shares of Myriad Genetics by 60.2% during the third quarter. Municipal Employees Retirement System of Michigan now owns 25,760 shares of the company’s stock valued at $932,000 after acquiring an additional 9,680 shares during the last quarter.

The company has a market capitalization of $2,070.00, a price-to-earnings ratio of 26.84, a P/E/G ratio of 1.83 and a beta of 0.24. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.26 and a current ratio of 1.46.

COPYRIGHT VIOLATION WARNING: “Myriad Genetics, Inc. (MYGN) Trading Up 6.5% Following Strong Earnings” was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/07/myriad-genetics-inc-mygn-trading-up-6-5-following-strong-earnings.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.